COMPASS Pathways plc

The company is a clinical-stage biotechnology business that develops evidence-based therapeutic options for serious mental health conditions. Its primary product candidate is COMP360, an investigational formulation of pharmaceutical-grade crystalline psilocybin designed to induce rapid and durable treatment responses. The firm focuses on therapeutic indications that include treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa. Its target patient populations consist of individuals living with severe psychiatric disorders who do not experience adequate relief from existing conventional medications and therapies.

The company conducts clinical research operations internationally across North America and Europe, with study sites in Ireland and the United States. Its clinical trial network has included twenty-two sites across ten countries for its mid-stage studies, alongside collaboration partnerships with multiple healthcare delivery systems in the United States. The provided text does not identify the company's headquarters.

Summary of the business section of COMPASS Pathways's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 156 employees, which represented a decrease of 6.0% compared to the prior year, of whom 101 employees are engaged in research and development activities and 55 employees are engaged in general administrative functions.”